Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: Subgroup analysis of a randomized phase 3 trial

1. Zinzani, P.L.
2. Khuageva, N.K.
3. Wang, H.
4. Garicochea, B.
5. Walewski, J.
6. Van Hoof, A.
7. Soubeyran, P.
8. Caballero, D.
9. Buckstein, R.
10. Esseltine, D.-L.
11. Theocharous, P.
12. Enny, C.
13. Zhu, E.
14. Elsayed, Y.A.
15. Coiffier, B.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1186/1756-8722-5-67 GOOGLE SCHOLAR lock_openOpen access editor